BC
ALLO icon

Bridgefront Capital’s Allogene Therapeutics ALLO Stock Holding History

Bridgefront Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,781
Closed -$53.6K – 381
2023
Q2 		$53.6K Sell
10,781
-28,746
-73% -$155K 0.03% 427
2023
Q1 		$195K Buy
+39,527
New +$253K 0.12% 348
2022
Q4 		– Sell
-20,512
Closed -$222K – 356
2022
Q3 		$222K Buy
+20,512
New +$279K 0.23% 203
2021
Q1 		– Sell
-14,670
Closed -$370K – 654
2020
Q4 		$370K Buy
+14,670
New +$478K 0.13% 299

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's ALLO Position: Q3 2023 in Review

Bridgefront Capital sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 10,781 shares — an estimated $53.6K sold.

Bridgefront Capital first reported a position in ALLO in Q4 2020 and held it in 4 quarters. The position peaked at $370K in Q4 2020. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Bridgefront Capital reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bridgefront Capital sold 10,781 Allogene Therapeutics shares in Q3 2023, an estimated $53.6K.
  • Bridgefront Capital first reported a position in Allogene Therapeutics in Q4 2020 and held it in 4 quarters.
  • Bridgefront Capital's Allogene Therapeutics position peaked at $370K in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Bridgefront Capital's 13F filing for Q3 2023, filed 14 Nov 2023.